A catalyst don’t appear in the overall stoichiometry of the reaction it catalyzes, but it must appear in at least one of the elementary reactions in the mechanism for the catalyzed reaction. 125995-03-1, Name is Atorvastatin lactone, molecular formula is C33H33FN2O4. In a Chapter，once mentioned of 125995-03-1, COA of Formula: C33H33FN2O4
The development of synthetic routes to atorvastatin, probably the most commercially successful small molecule drug ever launched, has spanned some 25 years. The changing requirements of synthetic routes and the reagents encompassed by these have paralleled the life-cycle of the drug. These requirements have shifted from flexibility, reliability and speed in the medicinal chemistry phase to suitability for scale-up and overall yield in the development phase. Emphasis on routes that exhibit low cost and reduced environmental impact has come to the forefront in manufacturing. The desire for increasingly efficient and low-hazard chemistry in the development and manufacture of this drug has been both accompanied by and provided a stimulus to the rise of asymmetric catalysis, especially biocatalysis. The implementation of asymmetric catalysis, and its integration into the overall route alongside other improvements has had a major impact in increased efficiency and minimisation of hazards in production of this drug.
Sometimes chemists are able to propose two or more mechanisms that are consistent with the available data.COA of Formula: C33H33FN2O4, If a proposed mechanism predicts the wrong experimental rate law, however, the mechanism must be incorrect.Welcome to check out more blogs about 125995-03-1, in my other articles.
Reference：
Tetrahydropyran – Wikipedia,
Tetrahydropyran – an overview | ScienceDirect Topics